Renaissance Technologies LLC Sells 229,170 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Renaissance Technologies LLC decreased its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 89.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 26,110 shares of the biopharmaceutical company's stock after selling 229,170 shares during the quarter. Renaissance Technologies LLC's holdings in Halozyme Therapeutics were worth $1,248,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Venturi Wealth Management LLC acquired a new stake in Halozyme Therapeutics in the fourth quarter valued at $69,000. Retirement Systems of Alabama increased its position in Halozyme Therapeutics by 23.5% during the 3rd quarter. Retirement Systems of Alabama now owns 389,268 shares of the biopharmaceutical company's stock worth $22,282,000 after purchasing an additional 74,173 shares in the last quarter. Shaker Investments LLC OH raised its stake in Halozyme Therapeutics by 12.3% during the fourth quarter. Shaker Investments LLC OH now owns 75,326 shares of the biopharmaceutical company's stock worth $3,601,000 after purchasing an additional 8,249 shares during the period. Foster & Motley Inc. boosted its holdings in shares of Halozyme Therapeutics by 118.6% in the 4th quarter. Foster & Motley Inc. now owns 23,280 shares of the biopharmaceutical company's stock valued at $1,113,000 after purchasing an additional 12,630 shares during the last quarter. Finally, Jennison Associates LLC purchased a new stake in shares of Halozyme Therapeutics during the 4th quarter valued at $731,000. Institutional investors and hedge funds own 97.79% of the company's stock.

Halozyme Therapeutics Price Performance

Halozyme Therapeutics stock traded down $0.67 during trading hours on Monday, hitting $60.52. 75,739 shares of the company traded hands, compared to its average volume of 1,438,370. The firm's 50-day simple moving average is $60.79 and its two-hundred day simple moving average is $55.41. The firm has a market cap of $7.48 billion, a P/E ratio of 17.60, a P/E/G ratio of 0.42 and a beta of 1.26. Halozyme Therapeutics, Inc. has a 1-year low of $40.19 and a 1-year high of $66.00. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, topping the consensus estimate of $1.17 by $0.02. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The firm had revenue of $298.01 million for the quarter, compared to analysts' expectations of $285.74 million. As a group, analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 5,000 shares of the firm's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $58.69, for a total transaction of $293,450.00. Following the completion of the sale, the director now directly owns 33,611 shares in the company, valued at approximately $1,972,629.59. This trade represents a 12.95 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $58.05, for a total transaction of $580,500.00. Following the completion of the sale, the senior vice president now directly owns 185,453 shares of the company's stock, valued at $10,765,546.65. This trade represents a 5.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 21,697 shares of company stock worth $1,276,552. Company insiders own 2.40% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on HALO. Benchmark reissued a "buy" rating and set a $75.00 price target on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. Piper Sandler upped their price target on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a "neutral" rating in a report on Friday, January 10th. JPMorgan Chase & Co. upped their target price on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the company a "neutral" rating in a research note on Monday, April 21st. HC Wainwright reaffirmed a "buy" rating and set a $72.00 target price on shares of Halozyme Therapeutics in a research report on Friday, April 25th. Finally, Wells Fargo & Company lowered their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating for the company in a research note on Monday, January 13th. Four analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $62.89.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.